A carregar...
Lapatinib for the treatment of breast cancer in the People’s Republic of China
Lapatinib is an oral, small-molecule, reversible inhibitor of both epidermal growth factor receptor and human epidermal growth factor receptor–2 (HER2) tyrosine kinases. In March 2007, the US Food and Drug Administration approved lapatinib for use in combination with capecitabine for the treatment o...
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4125370/ https://ncbi.nlm.nih.gov/pubmed/25114575 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S60586 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|